University of Ioannina
Επίδραση υπολιπιδαιμικών φαρμάκων στη μάζα της Lp-PLA2 και σε άλλους δείκτες φλεγμονής σε άτομα με πρωτοπαθή υπερλιπιδαιμία
Abstract
dc:descriptionThe metabolism of lipids results in the production of lipoproteins, which are involved in the process of atherosclerosis. Low density lipoprotein (LDL) play a key role in the onset of atherosclerosis, while high density lipoprotein (HDL) have antiatherogenic properties through their participation in the reverse cholesterol transport, while protecting the endothelial function of blood vessels. The attempts to intervene in the levels of these lipoproteins led to the discovery of several classes of lipid-lowering drugs like statins, fibrates, ezetimibe, bile acid binding resins, nicotinic acid and omega-3 fatty acids. Each of these drugs affects the metabolism of lipids through different ways and exerts various results in the reduction of both the lipoprotein levels and the risk for cardiovascular disease (CVD). It has also been observed that the beneficial effect of certain lipid-lowering drugs in the appearance of CVD is attributed not only to their direct action on lipid metabolism but also to further mechanisms called pleiotropic actions. Such pleiotropic actions include the antioxidant, anti-inflammatory and antithrombotic properties of such agents. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme that plays an important role in the inflammatory process that characterizes atherosclerosis. Lp-PLA2 is produced by inflammatory cells, is associated primarily with LDL and less with other lipoproteins and normally hydrolyses the platelet activating factor (PAF), a mediator of inflammation, thus exerting tight control on serum PAF levels. Simultaneously, it hydrolyses oxidatively modified LDL leading to the generation of proinflammatory products. Elevated serum levels of Lp-PLA2 have been associated with increased CVD risk in healthy persons and in patients with vascular disease. The purpose of this study was to investigate the effect of three lipid-lowering drugs (ezetimibe, rosuvastatin and fenofibrate), which exert their action through different mechanisms, on lipid profile and on Lp-PLA2 activity, mass and specific activity in LDL, HDL and their subfractions in three different populations. According to the study results, ezetimibe significantly reduced TCHOL, LDL-CHOL and HDL-CHOL as well as the levels of apoB. There was no effect on the proportion of sdLDL or the mean diameter of LDL particles. Regarding Lp-PLA2, ezetimibe decreased both plasma activity and mass without affecting its specific activity or the ratios of activity and mass to apoB. Furthermore, ezetimibe reduced the HDL Lp-PLA2 activity and mass without altering its specific activity. Finally, since the largest proportion of enzyme activity of LDL and HDL is located in the subfractions LDL-5 and HDL-3c respectively, ezetimibe reduced the activity and mass of Lp-PLA2 while it did not affect the specific activity of the enzyme in the subfractions. Rosuvastatin induced a significant decrease in TCHOL, in LDL-CHOL and in the levels of ApoB. The levels of HDL-CHOL, the percentage of sdLDL and the mean diameter of LDL particles remained unchanged. It decreased plasma Lp-PLA2 activity and mass without reducing its specific activity. It also decreased the HDL-Lp-PLA2 activity and mass, while the specific enzyme activity remained unaffected. Finally, rosuvastatin decreased the Lp-PLA2 activity and mass in the LDL-5 subfraction without changing its specific activity, while there were no changes in activity, mass and specific enzyme activity in HDL-3c subfraction. Fenofibrate reduced TCHOL, LDL-CHOL and apoB while it increased HDL-CHOL. Moreover, it reduced the percentage of sdLDL and increased the mean diameter of LDL particles and reduced both activity and mass of Lp-PLA2, while it increased the specific activity of the enzyme in plasma. Finally, fenofibrate increased the HDL activity and mass of the enzyme, mainly in HDL-3c subfraction, while it decreased the activity and mass of the enzyme in LDL-5 subfraction. The enzyme specific activity in both total HDL and in HDL-3c and LDL-5 subfractions remained unchanged.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2011
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Saougos, Vasilios
- Σαούγκος, Βασίλειος
Subjects
dc:subject × 18- Μάζα Lp-PLA2
- Ενεργότητα Lp-PLA2
- Λιποπρωτεΐνες
- Ροσουβαστατίνη
- Εζετιμίμπη
- Φαινοφιμπράτη
- Υποκλάσματα λιποπρωτεϊνών
- Lp-PLA2 mass
- Lp-pla2 activity
- Lipoproteins
- Lipoprotein subfractions
- Rosuvastatin
- Ezetimibe
- Fenofibrate
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/26050